Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808223 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2 study of Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT00808223 is a Phase 2 study of Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00808223, a Phase 2 study of Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
Conditions Studied
Interventions
- BIOLOGICAL alefacept
Study Locations (5)
Other
- First Municipal Hospital for Active Treatment - Sofia - Sofia
- Skin and STD Clinical Centre - Riga
- Department of Dermatology No.17, Children Clinical Hospital - Riga
California
- Pediatric and Adolescent Dermatology - San Diego
Kentucky
- Physicians Skin Care, PLLC - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808223
The ClinicalTrials.gov registry entry for NCT00808223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which alefacept is the first listed.
NCT00808223 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00808223 about?
NCT00808223 is a clinical study titled "Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis". To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
What is the current status of trial NCT00808223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2012-02.
What conditions does trial NCT00808223 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00808223?
The interventions under investigation include: alefacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00808223?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808223 being conducted?
This trial has 5 study locations across California, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.